Speaker :

Dr. Babita Kataria, Medical Oncologist, Delhi

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial

Author: Junjie Li 

Citation: Journal of Clinical Oncology 38, no. 16 (June 01, 2020) 1774-1784

Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage  Triple-Negative Breast Cancer Who Had Received Standard Treatment The SYSUCC-001 Randomized Clinical Trial

Author: XI Wang 

Citation: JAMA. Published online December 10, 2020. doi:10.1001/jama.2020.23370 

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001)

Author: XI Wang

Citation: Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 507-507